Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results

Financial Performance - Intellia Therapeutics reported cash, cash equivalents, and marketable securities of $605.1 million as of December 31, 2025, down from $861.7 million in the prior year [1] - The company expects its cash reserves to fund operations into the second half of 2027, including the anticipated U.S. commercial launch of lonvo-z for HAE [1] Revenue and Expenses - Collaboration revenue for the quarter was $23.0 million, an increase from $12.9 million in the prior year, driven by a $9.0 million revenue recognition from the termination of a license agreement with SparingVision SAS and increased cost reimbursements from collaboration with Regeneron [2] - Research and development expenses for the quarter were $88.7 million, down from $116.9 million in the prior year [2] Company Overview - Intellia Therapeutics is a clinical-stage genome editing company focused on developing curative therapeutics using the CRISPR/Cas9 system [3]